Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Short term Debt (2020 - 2021)

BridgeBio Pharma (BBIO) has disclosed Short term Debt for 2 consecutive years, with $3.6 million as the latest value for Q1 2021.

  • Quarterly Short term Debt changed N/A to $3.6 million in Q1 2021 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Mar 2021, changed N/A year-over-year, with the annual reading at $1.5 million for FY2020, N/A changed from the prior year.
  • Short term Debt hit $3.6 million in Q1 2021 for BridgeBio Pharma, up from $1.5 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $3.6 million in Q1 2021 to a low of $1.5 million in Q4 2020.